- Home
- Na Medication Assisted Mat Treatment Market
NA Medication Assisted (MAT) Treatment Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-386 | No of pages: 232 | Format:
The North America medication-assisted treatment (MAT) market is projected to register a substantial CAGR of 9.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2019, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
Market Segmentation:
North America Medication-Assisted Treatment (MAT) Market, By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram, and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral, and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals, Specialty Centres, Homecare, and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy, and Others), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of North America medication-assisted treatment (MAT) are:
The rise in the population receiving medication-assisted treatment (MAT)
Availability of reimbursement for medication-assisted treatment (MAT)
Market Players:
Some of the major players operating in the North America medication-assisted treatment (MAT) market are:
Indivior PLC
Orexo US Inc (a subsidiary of Orexo AB)
Recovery Centers of America
Alkermes
Sun Pharmaceutical Industries Ltd.
Purdue Pharma L.P.
Taj Pharmaceuticals Limited
Lannett
Hikma Pharmaceuticals PLC
Pfizer Inc.
Pinnacle Treatment Center
American Addiction Centers
Adamis Pharmaceuticals Corporation
Glenmark Pharmaceutical Inc.
Viatris Inc.
Mallinckrodt
Alvogen
VistaPharm, Inc.
Teva Pharmaceutical Industries Ltd.
Dr. Reddys Laboratories Ltd.
Amneal Pharmaceuticals LLC.
Titan Pharmaceuticals, Inc.
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 49
1.1 OBJECTIVES OF THE STUDY 49
1.2 MARKET DEFINITION 49
1.3 OVERVIEW OF NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET 49
1.4 CURRENCY AND PRICING 52
1.5 LIMITATIONS 52
1.6 MARKETS COVERED 53
2 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION 57
2.1 MARKETS COVERED 57
2.2 GEOGRAPHICAL SCOPE 58
2.3 YEARS CONSIDERED FOR THE STUDY 59
2.4 DBMR TRIPOD DATA VALIDATION MODEL 60
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 63
2.6 MULTIVARIATE MODELLING 64
2.7 PRODUCT SEGMENT LIFELINE CURVE 64
2.8 DBMR MARKET POSITION GRID 65
2.9 VENDOR SHARE ANALYSIS 67
2.10 MARKET END USER COVERAGE GRID 68
2.11 SECONDARY SOURCES 69
3 EXECUTIVE SUMMARY 70
4 PREMIUM INSIGHTS 74
4.1 EPIDEMIOLOGY 75
4.2 PESTEL 76
4.3 PORTER'S FIVE FORCES MODEL 77
4.4 ANNUAL INCIDENCE OF SUBJECTS ENTERING MEDICATION-ASSISTED TREATMENT IN ALCOHOL, OPIOID USE DISORDER, AND OPIOID OVERDOSE PREVENTION (2021) 78
4.5 ANNUAL NUMBER OF TREATMENTS WITH CLONIDINE AND WITH LOFEXIDINE IN OPIOID USE DISORDER AND OPIOID OVERDOSE PREVENTION (2021) 78
4.6 ANNUAL INCIDENCE OF INDIVIDUALS RE-ENTERING MEDICATION-ASSISTED TREATMENT. FOR EXAMPLE, SOMEONE MAY DROP OUT OF TREATMENT AND RESTART TREATMENT LATER (2021) 79
4.7 ANNUAL USE OF NALTREXONE INJECTION AS PART OF TREATMENT FOR THE INITIAL WITHDRAWAL FROM OPIOIDS, AND ANNUAL MAINTENANCE THERAPY USING NALTREXONE INJECTION (2021) 79
4.8 PIPELINE ANALYSIS FOR MEDICATION-ASSISTED TREATMENT (MAT) MARKET 80
5 NORTH AMERICA MEDICATION-ASSISTED TREATMENT MARKET: REGULATIONS 81
6 MARKET OVERVIEW 84
6.1 DRIVERS 86
6.1.1 THE RISE IN INCIDENCE OF ALCOHOL USE DISORDER AND OPIOID USE DISORDERS 86
6.1.2 THE FUNDING BY THE GOVERNMENT FOR MEDICATION-ASSISTED TREATMENT (MAT) 87
6.1.3 THE RISE IN THE POPULATION RECEIVING MEDICATION-ASSISTED TREATMENT (MAT) AND MEDICATION-ASSISTED AWARENESS PROGRAMMESMEDICATION-ASSISTED TREATMENT (MAT) 87
6.1.4 USE OF REIMBURSEMENT FOR MEDICATION-ASSISTED TREATMENT (MAT) 88
6.2 RESTRAINTS 89
6.2.1 SIDE EFFECTS OF DRUGS USED IN MEDICATION-ASSISTED TREATMENT (MAT) 89
6.2.2 ETHICAL ISSUES RELATED TO USE OF MEDICATION-ASSISTED TREATMENTMEDICATION-ASSISTED TREATMENT (MAT) 89
6.2.3 RISE IN PRODUCT RECALLS 89
6.3 OPPORTUNITIES 90
6.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 90
6.3.2 RISE IN HEALTHCARE EXPENDITURE 91
6.4 CHALLENGES 91
6.4.1 THE LACK OF SKILLED PROFESSIONALS, REQUIRED FOR MEDICATION-ASSISTED TREATMENT 91
6.4.2 STRINGENT REGULATIONS 92
6.4.3 DISCONTINUATION OF MEDICATION-ASSISTED TREATMENT (MAT) 93
7 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE 94
7.1 OVERVIEW 95
7.2 MEDICATION 98
7.2.1 OPIOID DEPENDENCY MEDICATION 99
7.2.1.1 BUPRENORPHINE AND NALOXONE 99
7.2.1.2 BUPRENORPHINE 99
7.2.1.3 METHADONE 99
7.2.1.4 NALTREXONE 100
7.2.2 ALCOHOL USE DISORDER MEDICATIONS 100
7.2.2.1 NALTREXONE 100
7.2.2.2 DISULFIRAM 100
7.2.2.3 ACAMPROSATE 100
7.2.3 OPIOID OVERDOSE PREVENTION MEDICATION 100
7.2.3.1 NALOXONE 101
7.3 THERAPY 101
7.3.1 BEHAVIORAL THERAPY 102
7.3.2 EDUCATIONAL THERAPY 102
7.3.3 COUNSELLING 102
7.3.4 VOCATIONAL THERAPY 102
7.3.5 OTHERS 103
8 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS 104
8.1 OVERVIEW 105
8.2 BUPRENORPHINE AND NALOXONE 108
8.3 NALTREXONE 108
8.4 BUPRENORPHINE 110
8.5 METHADONE 110
8.6 NALOXONE 111
8.7 DISULFIRAM 112
8.8 ACAMPROSATE 113
9 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE 114
9.1 OVERVIEW 115
9.2 GENERICS 118
9.3 BRANDED 118
9.3.1 SUBOXONE 119
9.3.2 VIVITROL 119
9.3.3 BUTRANS 119
9.3.4 ZUBSOLV 120
9.3.5 PROBUPHINE 120
9.3.6 OTHERS 120
10 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM 121
10.1 OVERVIEW 122
10.2 IMMEDIATE RELEASE 125
10.3 EXTENDED RELEASE 125
11 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION 127
11.1 OVERVIEW 128
11.2 ORAL 131
11.2.1 TABLET 132
11.2.2 SUBLINGUAL FILM 132
11.2.3 OTHERS 132
11.3 PARENTERAL 132
11.3.1 SOLUTION 133
11.3.2 SUSPENSION 133
11.4 OTHERS 134
12 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE 135
12.1 OVERVIEW 136
12.2 ADULTS 139
12.3 TEENAGE 139
13 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER 141
13.1 OVERVIEW 142
13.2 REHABILITATION CLINICS 145
13.3 HOSPITALS 145
13.4 SPECIALTY CENTERS 146
13.5 HOMECARE 147
13.6 OTHERS 148
14 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL 149
14.1 OVERVIEW 150
14.2 HOSPITAL PHARMACY 153
14.3 DIRECT TENDER 153
14.4 RETAIL PHARMACY 154
14.5 ONLINE PHARMACY 155
14.6 OTHERS 156
15 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION 157
15.1 NORTH AMERICA 158
15.1.1 U.S. 168
15.1.2 CANADA 173
15.1.3 MEXICO 178
16 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY LANDSCAPE 183
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 183
17 SWOT ANALYSIS 184
18 COMPANY PROFILE 185
18.1 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2021) 185
18.1.1 COMPANY SNAPSHOT 185
18.1.2 REVENUE ANALYSIS 186
18.1.3 COMPANY SHARE ANALYSIS 186
18.1.4 PRODUCT PORTFOLIO 186
18.1.5 RECENT DEVELOPMENTS 187
18.2 INDIVOR PLC (2021) 188
18.2.1 COMPANY SNAPSHOT 188
18.2.2 REVENUE ANALYSIS 188
18.2.3 COMPANY SHARE ANALYSIS 189
18.2.4 PRODUCT PORTFOLIO 189
18.2.5 RECENT DEVELOPMENTS 190
18.3 VIATRIS INC (2021) 191
18.3.1 COMPANY SNAPSHOT 191
18.3.2 REVENUE ANALYSIS 191
18.3.3 COMPANY SHARE ANALYSIS 192
18.3.4 PRODUCT PORTFOLIO 192
18.3.5 RECENT DEVELOPMENTS 192
18.4 SUN PHARMACEUTICAL INDUSTRIES LTD (2021) 193
18.4.1 COMPANY SNAPSHOT 193
18.4.2 REVENUE ANALYSIS 193
18.4.3 COMPANY SHARE ANALYSIS 194
18.4.4 PRODUCT PORTFOLIO 194
18.4.5 RECENT DEVELOPMENTS 194
18.5 ALKERMES (2021) 195
18.5.1 COMPANY SNAPSHOT 195
18.5.2 REVENUE ANALYSIS 195
18.5.3 COMPANY SHARE ANALYSIS 196
18.5.4 PRODUCT PORTFOLIO 196
18.5.5 RECENT DEVELOPMENTS 197
18.6 PURDUE PHARMA L.P. (2021) 198
18.6.1 COMPANY SNAPSHOT 198
18.6.2 PRODUCT PORTFOLIO 198
18.6.3 RECENT DEVELOPMENTS 198
18.7 PFIZER (2021) 199
18.7.1 COMPANY SNAPSHOT 199
18.7.2 REVENUE ANALYSIS 199
18.7.3 PRODUCT PORTFOLIO 200
18.7.4 RECENT DEVELOPMENTS 200
18.8 GLENMARK PHARMACEUTICAL INC (2021) 201
18.8.1 COMPANY SNAPSHOT 201
18.8.2 REVENUE ANALYSIS 201
18.8.3 PRODUCT PORTFOLIO 202
18.8.4 RECENT DEVELOPMENTS 202
18.9 DR. REDDYS LABORATORIES LTD (2021) 203
18.9.1 COMPANY SNAPSHOT 203
18.9.2 REVENUE ANALYSIS 203
18.9.3 PRODUCT PORTFOLIO 204
18.9.4 RECENT DEVELOPMENTS 204
18.10 ALVOGEN (2021) 205
18.10.1 COMPANY SNAPSHOT 205
18.10.2 PRODUCT PORTFOLIO 205
18.10.3 RECENT DEVELOPMENTS 205
18.11 ADAMIS PHARMACEUTICALS CORPORATION (2021) 206
18.11.1 COMPANY SNAPSHOT 206
18.11.2 REVENUE ANALYSIS 206
18.11.3 PRODUCT PORTFOLIO 207
18.11.4 RECENT DEVELOPMENTS 207
18.12 ACCORD HEALTHCARE (A SUBSIDIARY OF INTAS PHARMACEUTICALS) 208
18.12.1 COMPANY SNAPSHOT 208
18.12.2 PRODUCT PORTFOLIO 208
18.12.3 RECENT DEVELOPMENTS 209
18.13 AMNEAL PHARMACEUTICALS LLC (2021) 210
18.13.1 COMPANY SNAPSHOT 210
18.13.2 REVENUE ANALYSIS 210
18.13.3 PRODUCT PORTFOLIO 211
18.13.4 RECENT DEVELOPMENTS 211
18.14 AMERICAN ADDICTION CENTERS (2021) 212
18.14.1 COMPANY SNAPSHOT 212
18.14.2 PRODUCT PORTFOLIO 212
18.14.3 RECENT DEVELOPMENTS 212
18.15 HIKMA PHARMACEUTICALS PLC (2021) 213
18.15.1 COMPANY SNAPSHOT 213
18.15.2 REVENUE ANALYSIS 213
18.15.3 PRODUCT PORTFOLIO 214
18.15.4 RECENT DEVELOPMENTS 214
18.16 LANNETT (2021) 215
18.16.1 COMPANY SNAPSHOT 215
18.16.2 REVENUE ANALYSIS 215
18.16.3 PRODUCT PORTFOLIO 216
18.16.4 RECENT DEVELOPMENT 216
18.17 MALLINCKRODT (2021) 217
18.17.1 COMPANY SNAPSHOT 217
18.17.2 REVENUE ANALYSIS 217
18.17.3 PRODUCT PORTFOLIO 218
18.17.4 RECENT DEVELOPMENT 218
18.18 OREXO US INC (A SUBSIDIARY OF OREXO, INC) (2021) 219
18.18.1 COMPANY SNAPSHOT 219
18.18.2 REVENUE ANALYSIS 219
18.18.3 PRODUCT PORTFOLIO 220
18.18.4 RECENT DEVELOPMENT 220
18.19 PINNACLE TREATMENT CENTERS 221
18.19.1 COMPANY SNAPSHOT 221
18.19.2 PRODUCT PORTFOLIO 221
18.19.3 RECENT DEVELOPMENT 221
18.20 RECOVERY CENTERS OF AMERICA 222
18.20.1 COMPANY SNAPSHOT 222
18.20.2 PRODUCT PORTFOLIO 222
18.20.3 RECENT DEVELOPMENTS 223
18.21 TAJ PHARMACEUTICALS LIMITED 224
18.21.1 COMPANY SNAPSHOT 224
18.21.2 PRODUCT PORTFOLIO 224
18.21.3 RECENT DEVELOPMENTS 224
18.22 TITAN PHARMACEUTICALS (2021) 225
18.22.1 COMPANY SNAPSHOT 225
18.22.2 REVENUE ANALYSIS 225
18.22.3 PRODUCT PORTFOLIO 226
18.22.4 RECENT DEVELOPMENTS 226
18.23 VISTAPHARM, INC (A SUBSIDIARY OF VERTICE PHARMA, LLC. (2021)) 227
18.23.1 COMPANY SNAPSHOT 227
18.23.2 PRODUCT PORTFOLIO 227
18.23.3 RECENT DEVELOPMENTS 227
19 QUESTIONNAIRE 228
20 RELATED REPORTS 232
Segmentation
Short Description
North America Medication-Assisted Treatment (MAT) Market, By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram, and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral, and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals, Specialty Centres, Homecare, and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy, and Others), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2029
Market Definition:
Medication-assisted treatment (MAT), involves the use of medications, combined with counseling and behavioral therapies, to provide a complete patient approach for treating substance use disorders. MAT is primarily used to treat addiction to opioids such as heroin and prescription pain relievers. The aim of MAT is proper recovery, which includes improved patient survival, increased treatment retention, reduced illicit response, and grow in pregnancy outcomes among women.
The Food and Drug Administration (FDA) approved three drugs for clinical use which are buprenorphine, methadone, and naltrexone. Medication-assisted treatment (MAT) is applied to cure alcohol use disorder, opioid dependency medication, and opioid overdose prevention medication. Alcohol use disorder (AUD) is a medical condition characterized by an impaired ability to stop alcohol use despite adverse social, occupational, or health consequences. Acamprosate, disulfiram, and naltrexone are the most common medications used to treat alcohol use disorder (AUD). The opioid dependency medication, rise in addiction for opioids among patients. Buprenorphine, methadone and naltrexone are used to treat opioid use disorders to short-acting opioids such as heroin, morphine, and codeine, as well as semi-synthetic opioids like oxycodone and hydrocodone. These MAT medications are safe for months, years, or even a lifetime. For opioid overdose prevention medication, naloxone is used to prevent opioid overdose by reversing the toxic effects of the overdose. According to the World Health Organization (WHO) and by Substance Abuse and Mental Health Services Administration (SAMHSA), naloxone is one of many medications considered essential to a functioning health care system.
Market Segmentation:
The North America medication-assisted treatment (MAT) market is categorized into eight segments: type, products, drug type, dosage form, route of administration, population type, end user, and distribution channel.
On the basis of type, the global medication-assisted treatment (MAT) market is segmented into medication and therapy
On the basis of product, the global medication-assisted treatment (MAT) market is segmented into buprenorphine and naloxone, naltrexone, buprenorphine, acamprosate, methadone, naloxone, and disulfiram
On the basis of drug type, the global medication-assisted treatment (MAT) market is segmented into branded and generics
On the basis of dosage form, the global medication-assisted treatment (MAT) market is segmented into extended-release and immediate-release
On the basis of route of administration, the global medication-assisted treatment (MAT) market is segmented into oral, parenteral, and others
On the basis of population type, the global medication-assisted treatment (MAT) market is segmented into children and teenage
On the basis of end user, the global medication-assisted treatment (MAT) market is segmented into rehabilitation clinics, hospitals, specialty centers, homecare, and others
On the basis of distribution channel, the global medication-assisted treatment (MAT) market is segmented into direct tender hospital pharmacy, retail pharmacy, online pharmacy, and others
Market Players
Some of the major players operating in the North America Medication-Assisted Treatment (MAT) market are:
Indivior PLC
Orexo US Inc (a subsidiary of Orexo AB)
Recovery Centers of America
Alkermes
Sun Pharmaceutical Industries Ltd.
Purdue Pharma L.P.
Taj Pharmaceuticals Limited
Lannett
Hikma Pharmaceuticals PLC
Pfizer Inc.
Pinnacle Treatment Center
American Addiction Centers
Adamis Pharmaceuticals Corporation
Glenmark Pharmaceutical Inc.
Viatris Inc.
Mallinckrodt
Alvogen
VistaPharm, Inc.
Teva Pharmaceutical Industries Ltd.
Dr. Reddys Laboratories Ltd.
Amneal Pharmaceuticals LLC.
Titan Pharmaceuticals, Inc.
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.